Long-term neuromuscular outcomes of west nile virus infection: A clinical and electromyographic evaluation of patients with a history of infection

Muscle and Nerve

Volumn 57, Issue 1, 2018, Pages 77-82

  Athar, Parveen ^a   Hasbun, Rodrigo ^a   Nolan, Melissa S ^b   Salazar, Lucrecia ^a   Woods, Steven P ^c   Sheikh, Kazim ^a   Murray, Kristy O ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

CMAPs; denervation; electromyography; SNAPs; West Nile virus

Indexed keywords

ADULT; AGED; ANTERIOR HORN CELL; ARTICLE; CHRONIC DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; NERVE CONDUCTION; NEUROMUSCULAR FUNCTION; OUTCOME ASSESSMENT; POLIOMYELITIS; PRIORITY JOURNAL; VERY ELDERLY; WEST NILE FEVER; WEST NILE VIRUS; CASE REPORT; COGNITIVE DEFECT; COMPLICATION; DISABILITY; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; DISABILITY EVALUATION; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASES; POLIOMYELITIS; TREATMENT OUTCOME; WEST NILE FEVER;

EID: 85037681160     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.25660     Document Type: Article

References (25)

1. Murray KO, Walker C, Gould E. The virology, epidemiology, and clinical impact of West Nile virus: a decade of advancements in research since its introduction into the Western Hemisphere. Epidemiol Infect 2011;139:807–817.
2. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, Cooper MJ, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001;358:261–264.
3. Sejvar JJ, Haddad MB, Tierney BC, Campbell GL, Marfin AA, van Gerpen JA, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003;290:511–515.
4. Murray KO, Baraniuk S, Resnick M, Arafat R, Kilborn C, Shallenberger R, et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002–2004. Vector Borne Zoonotic Dis 2008;8:167–174.
5. Murray KO, Garcia MN, Rahbar MH, Martinez D, Khuwaja SA, Arafat RR, et al. Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort. PLoS One 2014;9:e102953.
6. Murray K, Walker C, Herrington E, Lewis JA, McCormick J, Beasley DW, et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis 2010;201:2–4.
7. Nolan MS, Podoll AS, Hause AM, Akers KM, Finkel KW, Murray KO. Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort. PLoS One 2012;7:e40374.
8. Weatherhead JE, Miller VE, Garcia MN, Hasbun R, Salazar L, Dimachkie MM, et al. Long-term neurological outcomes in West Nile virus-infected patients: an observational study. Am J Trop Med Hyg 2015;92:1006–1012.
9. Sejvar JJ, Bode AV, Marfin AA, Campbell GL, Pape J, Biggerstaff BJ, et al. West Nile virus-associated flaccid paralysis outcome. Emerg Infect Dis 2006;12:514–516.
10. Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, et al. Persistence of virus-reactive serum immunoglobulin M antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003;9:376–379.
11. Prince HE, Tobler LH, Lape-Nixon M, Foster GA, Stramer SL, Busch MP. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol 2005;43:4316–4320.
12. Papa A, Danis K, Athanasiadou A, Delianidou M, Panagiotopoulos T. Persistence of West Nile virus immunoglobulin M antibodies, Greece. J Med Virol 2011;83:1857–1860.
13. Murray KO, Garcia MN, Yan C, Gorchakov R. Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus. Am J Trop Med Hyg 2013;89:996–1000.
14. Christou L. The global burden of bacterial and viral zoonotic infections. Clin Microbiol Infect 2011;17:326–330.
15. Prow NA, Hewlett EK, Faddy HM, Coiacetto F, Wang W, Cox T, et al. The Australian public is still vulnerable to emerging virulent strains of West Nile virus. Front Publ Health 2014;2:146.
16. Benjelloun A, El Harrak M, Belkadi B. West Nile disease epidemiology in North-West Africa: bibliographical review. Transbound Emerg Dis 2016;63:e153–159.
17. Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect 2007;44:1617–1624.
18. Leis AA, Szatmary G, Ross MA, Stokic DS. West Nile virus infection and myasthenia gravis. Muscle Nerve 2014;49:26–29.
19. Leis AA, Stokic DS. Neuromuscular manifestations of west nile virus infection. Front Neurol 2012;3:37.
20. Dyck PJ, Huges RAC, O'Brien PC. Quantitating overall neuropathic symptoms, impairments, and outcomes. In: Dyck PJ, O'Brien PC, editors. Peripheral neuropathy, 4th ed. Philadelphia: Elsevier; 2005. p 1031–1051.
21. Fratkin JD, Leis AA, Stokic DS, Slavinski SA, Geiss RW. Spinal cord neuropathology in human West Nile virus infection. Arch Pathol Lab Med 2004;128:533–537.
22. Ravits J, Hallett M, Baker M, Nilsson J, Dalakas M. Clinical and electromyographic studies of postpoliomyelitis muscular atrophy. Muscle Nerve 1990;13:667–674.
23. Dalakas MC. The post-polio syndrome as an evolved clinical entity. Definition and clinical description. Ann NY Acad Sci 1995;753:68–80.
24. Sejvar JJ, Bode AV, Marfin AA, Campbell GL, Ewing D, Mazowiecki M, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis 2005;11:1021–1027.
25. U.S. Centers for Disease Control and Prevention. West Nile virus disease cases and deaths reported to CDC by year and clinical presentation, 1999–2013. Hyattsville, MD: CDC; 2017.